Literature DB >> 30692356

[Two Cases of CT-Guided Radiofrequency Ablation Therapy for Pelvic Recurrence from Rectal Cancer].

Michiko Hamanaka1, Masafumi Noda, Ayako Imada, Jihyung Song, Kei Kimura, Akihito Babaya, Masayoshi Kobayashi, Kiyoshi Tsukamoto, Haruyuki Takaki, Tomoki Yamano, Masataka Ikeda, Koichiro Yamakado, Naohiro Tomita.   

Abstract

We experienced 2 cases of pelvic recurrence from rectal cancer. These patients received radiofrequency ablation(RFA) therapy. Case 1 was a 76-year-old man who underwent intersphincteric resection for lower rectal cancer in October 2013. In May 2015, the patient received systemic chemotherapy for multiple lung metastases and pelvic local recurrence. In January 2017, RFA was performed to reduce the pain of the pelvic recurrence. Immediately after RFA, the pain markedly reduced, and 2 months after treatment, the patient discontinued his pain therapy. Case 2 was a 48-year-old man who underwent Hartmann 's procedure for ulcerative colitis with rectal cancer in November 2011. In July 2012, we performed abdominoperineal resection for rectal cancer that developed in the remnant rectum. In November 2012, he received systemic chemotherapy for multiple lung metastases and pelvic recurrence. In addition, we performed stereotactic radiotherapy(SRT)for the pelvic recurrence. In May 2016, because he developed bilateral hydronephrosis and painful pelvic recurrence, we performed bilateral nephrostomy and RFA for the painful pelvic recurrence. After RFA, pain reduced, but he developed a pelvic abscess that was treated by CT-guided drainage. He underwent complete ablation for the recurrent pelvic mass 2 years after RFA but died of exacerbation of multiple lung metastases. CT-guided RFA for painful pelvic recurrence from rectal cancer can be considered a feasible and effective treatment to reduce pain.

Entities:  

Mesh:

Year:  2018        PMID: 30692356

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Treatment efficacy and prognosis analysis in locally advanced or metastatic colorectal cancer patients with hydronephrosis.

Authors:  Gangling Tong; Boran Chen; Mingying Zhang; Tianyu Wang; Xuan Wu; Yuye Yan; Shubin Wang; Shuluan Li
Journal:  Mol Clin Oncol       Date:  2022-04-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.